We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 22, 2022 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: https://www.zacks.com/stock/news/1956032/5-cheap-healthcare-stocks-in-2022
5 Cheap Healthcare Stocks in 2022
Welcome to Episode #290 of the Value Investor Podcast.
(0:45) - Are There Value Stocks In The Healthcare Sector?
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks.
There's plenty of value stocks in 2022 and they aren't all in energy or the banks.
Healthcare stocks got a big boost during the first year of the pandemic as investors rushed to buy diagnostic and vaccine companies. But that trade was quickly over as investors rotated into the large cap growth stocks.
But now, in the summer of 2022, healthcare stocks have been ignored and are cheap.
Screening for Top Cheap Healthcare Stocks
Tracey ran a basic screen using the Zacks Medical sector, a forward P/E under 15, a stock price above $5 a share, and a top Zacks Rank of #1 (Strong Buy) or #2 (Buy).
The top Zacks Ranks should give stocks that have rising earnings estimates which is key in this economic environment where companies have been cutting guidance.
Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines for customers in biopharma, vaccines, diagnostics and cell and gene therapy. It's a mid-cap company with a market cap of $6.9 billion.
In the first quarter, Maravai LifeSciences had record quarterly revenue, up 65% year-over-year.
But shares are down 35.8% year-to-date. After the sell-off, Maravai LifeSciences shares are cheap with a forward P/E of 14.5 as earnings are expected to rise 15.6% in 2022.
Sensus Healthcare is a small cap medical device company with a market cap of $169.7 million. It makes a non-surgical treatment, called Superficial Radiation Therapy, for non-melanoma skin cancer.
First quarter revenue was up 237% to $10.3 million.
Shares are up 41% year-to-date but Sensus Healthcare is still cheap with a forward P/E of 6.7. Earnings are expected to rise 512% this year.
Sensus Healthcare is a Zacks Rank #2 (Buy) stock.
Should value investors be looking at the small caps like Sensus Healthcare for long-term buying opportunities?
AbbVie is a large cap pharmaceutical company that owns Humira and popular aesthetic drugs Botox and Juvederm.
AbbVie shares are up about 10% year-to-date but are still cheap, with a forward P/E of 10.7.
Dividend investors are big fans of AbbVie, as it pays an attractive dividend yielding 3.8%.
Is AbbVie a place to hide out in 2022 during the market volatility?
What Else Do You Need to Know About Cheap Healthcare Stocks?
Tune into this week's podcast to find out.
[In full disclosure, Tracey owns shares of ABBV in her personal portfolio.]
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie
For Immediate Release
Chicago, IL – July 22, 2022 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: https://www.zacks.com/stock/news/1956032/5-cheap-healthcare-stocks-in-2022
5 Cheap Healthcare Stocks in 2022
Welcome to Episode #290 of the Value Investor Podcast.
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks.
There's plenty of value stocks in 2022 and they aren't all in energy or the banks.
Healthcare stocks got a big boost during the first year of the pandemic as investors rushed to buy diagnostic and vaccine companies. But that trade was quickly over as investors rotated into the large cap growth stocks.
But now, in the summer of 2022, healthcare stocks have been ignored and are cheap.
Screening for Top Cheap Healthcare Stocks
Tracey ran a basic screen using the Zacks Medical sector, a forward P/E under 15, a stock price above $5 a share, and a top Zacks Rank of #1 (Strong Buy) or #2 (Buy).
The top Zacks Ranks should give stocks that have rising earnings estimates which is key in this economic environment where companies have been cutting guidance.
This screen returned 16 stocks.
5 Cheap Healthcare Stocks in 2022
1. Merck (MRK - Free Report) )
Merck is one of the large global pharmaceutical companies. Shares are down 17.1% in 2022, even though earnings are expected to rise 21.6% in 2022.
Merck shares are cheap, with a forward P/E of 12.6. It's a Zacks Rank #1 (Strong Buy).
Investors also get a dividend yielding 2.9%.
Should Merck be on your short list?
2. Maravai LifeSciences (MRVI - Free Report) )
Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines for customers in biopharma, vaccines, diagnostics and cell and gene therapy. It's a mid-cap company with a market cap of $6.9 billion.
In the first quarter, Maravai LifeSciences had record quarterly revenue, up 65% year-over-year.
But shares are down 35.8% year-to-date. After the sell-off, Maravai LifeSciences shares are cheap with a forward P/E of 14.5 as earnings are expected to rise 15.6% in 2022.
It is a Zacks Rank #2 (Buy).
Is Maravai LifeSciences on sale?
3. Sensus Healthcare (SRTS - Free Report) )
Sensus Healthcare is a small cap medical device company with a market cap of $169.7 million. It makes a non-surgical treatment, called Superficial Radiation Therapy, for non-melanoma skin cancer.
First quarter revenue was up 237% to $10.3 million.
Shares are up 41% year-to-date but Sensus Healthcare is still cheap with a forward P/E of 6.7. Earnings are expected to rise 512% this year.
Sensus Healthcare is a Zacks Rank #2 (Buy) stock.
Should value investors be looking at the small caps like Sensus Healthcare for long-term buying opportunities?
4. PetIQ (PETQ - Free Report) )
PetIQ is a leading pet medication and wellness company. Not all healthcare opportunities are on the human side.
Shares have fallen 23.4% year-to-date and are down 51% over the last year. They were recently at 5-year lows.
PetIQ is cheap, at a forward P/E of 14.4. But is it cheap enough? Sales are expected to rise just 5.5% in 2022.
Should investors be waiting on the sidelines on PetIQ?
5. AbbVie (ABBV - Free Report) )
AbbVie is a large cap pharmaceutical company that owns Humira and popular aesthetic drugs Botox and Juvederm.
AbbVie shares are up about 10% year-to-date but are still cheap, with a forward P/E of 10.7.
Dividend investors are big fans of AbbVie, as it pays an attractive dividend yielding 3.8%.
Is AbbVie a place to hide out in 2022 during the market volatility?
What Else Do You Need to Know About Cheap Healthcare Stocks?
Tune into this week's podcast to find out.
[In full disclosure, Tracey owns shares of ABBV in her personal portfolio.]
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Tracey Ryniec is the Value Stock Strategist for Zacks.com. She is also the Editor of the Insider Trader and Value Investor services. You can follow her on twitter at @TraceyRyniec and she also hosts the Zacks Market Edge Podcast on iTunes.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.